Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Florida Formula: Free Goods In Exchange For Formulary Status

Executive Summary

Pfizer is offering Florida free goods in exchange for continued unrestricted access to its products on the state Medicaid formulary.

You may also be interested in...



Pfizer Florida Medicaid Program Yields Savings Of $42 Mil. After Two Years

Pfizer is in discussions with Florida's Agency for Health Care Administration about a potential expansion of the company's Medicaid disease management program

Pfizer Florida Medicaid Program Yields Savings Of $42 Mil. After Two Years

Pfizer is in discussions with Florida's Agency for Health Care Administration about a potential expansion of the company's Medicaid disease management program

Pfizer Optimistic On Florida Medicaid Deal Despite Legislative Setback

Pfizer is optimistic on the chances of renewing a contract for the Florida Medicaid "Healthy State" program based on the results of an upcoming cost-savings report

Related Content

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel